Subject: Immune System Switch Controls Destiny Of White Blood Cells
> May 26, 2000 - By increasing or decreasing levels of a specific protein,
researchers can control the developmental destiny of white blood cells.
> The finding represents the first evidence that mammalian immune system
cells respond to such a dual control mechanism. The discovery raises the
possibility that scientists might be able to use the developmental switch to
manipulate the immune system to produce specific disease-fighting cells.
Furthermore, throwing the switch by using drugs or gene therapy might
jump-start the proper development of immature blood cells whose maturation
is stalled in certain cancers.
> In an article in the May 26, 2000, issue of Science, Howard Hughes Medical
Institute investigator Harinder Singh and his colleague Rodney DeKoter
report that the concentration of the transcription factor PU.1 in progenitor
immune cells determines whether those cells become macrophages or B cells.
> Transcription factors are proteins that activate genes to transcribe their
information into messenger RNA. Macrophages are white blood cells that
attack bacteria and other invaders by engulfing and digesting them; while B
cells generate antibodies that tag pathogens bearing foreign proteins,
marking them for attack by other immune cells.
> In previous studies, Singh and his colleagues at the University of Chicago
showed that knocking out the PU.1 gene in mice eliminated the ability of
such mice to make white blood cells. The scientists found that PU.1 switched
on genes specific to progenitors of macrophages or B cells that were
necessary for their normal differentiation into mature cells.
> "This left us with a puzzle," said Singh. "If this transcription factor is
needed for development of different cell types in the immune system- each of
which expresses very different sets of genes- how could a single factor
participate in regulating these very diverse programs of gene expression?"
> In exploring PU.1's role in development, the researchers created a method
for isolating mutant mouse progenitor blood cells that lacked PU.1. Once
they had harvested the PU.1-deficient cells, they used a viral vector to
shuttle the PU.1 genes back into the cells.
> "We found that these cells that were otherwise blocked from developing any
further recovered their ability to differentiate properly into macrophages
or B cells when they received the gene for PU.1," said Singh.
> A striking result of this experiment, said Singh, was that the resulting
macrophages expressed high concentrations of the PU.1 protein, while the B
cells expressed low concentrations.
> "It was quite a surprise," said Singh. "Although there had been some
reports that PU.1 levels were different in macrophages and B cells, no one
had ascribed any functional significance to that difference."
> To explore the functional role of PU.1 levels in immune cell
differentiation, the researchers next raised the level of PU.1 in normal
progenitor cells. They found that higher PU.1 levels effectively caused the
cells to become macrophages, rather than B cells.
> And in a third set of experiments, the scientists inserted a truncated
form of the PU.1 protein into cells that lacked PU.1 and found that this
"weakened" transcription factor efficiently rescued the development of B
cells, but not of macrophages.
> "Thus, we have shown that a lower concentration or a lower activity state
translates into one developmental outcome for these cells, turning them into
B cells," said Singh. "And conversely, higher concentrations of the
regulator produce macrophages.
> "The idea that differing concentrations of a transcription factor can
control the development of different cell types from progenitors has been an
attractive and commonly held view among developmental biologists," said
Singh. "It has been exceedingly difficult, however, to show that this
principle is actually valid in any given organism."
> Singh noted that, while researchers had shown that developing fruit flies
use graded levels of certain transcription factors to control the generation
of different embryonic cell types, "there hasn't been strong evidence for
this mechanism in mammalian systems. Thus, we are providing good evidence
that concentration-based control exists in the immune system, and of course,
in mammals in general."
> Singh emphasized that despite PU.1's importance, it is certainly not the
lone determinant of immune cell differentiation.
> "We believe that development of different lineages of blood cells is
triggered by a combination of particular sets of transcription factors and
their levels relative to one another," he said.
> Understanding how PU.1 controls immune cell development could have
important medical implications, he noted.
> "Once we understand the regulatory circuitry that controls immune cell
development, we could exploit that knowledge to develop treatments that
direct progenitor cells to differentiate into particular cell types for
therapeutic purposes," he said.
> "Also, many cancers of the immune system involve interruption of blood
cell differentiation. It's possible that drugs or gene therapy could be
developed to increase PU.1 activity to unblock differentiation of these
cancer cells and make them become benign."
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email